 |
市场调查报告书
商品编码
1741274
整合酶抑制剂市场按药物、给药途径、分销管道和地区划分Integrase Inhibitors Market, By Drug, By Route of Administration, By Distribution Channel, By Geography |
||||||
整合酶抑制剂市场规模预计在 2025 年为 164.3 亿美元，预计到 2032 年将达到 242.2 亿美元，2025 年至 2032 年的复合年增长率为 5.7%。
| 分析范围 | 分析详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 市场规模（2025年） | 164.3亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期内的复合年增长率（2025-2032） | 5.70% | 预计金额（2032年） | 242.2亿美元 |
整合酶抑制剂是一类相对较新的抗逆转录病毒药物，用于治疗爱滋病毒/爱滋病。整合酶抑制剂透过特异性抑制爱滋病毒整合酶发挥作用，整合酶是爱滋病毒基因组在宿主细胞内复製所必需的逆转录病毒酶。整合酶抑制剂阻止爱滋病毒 DNA 整合到受感染细胞的染色体 DNA 中，从而防止新的爱滋病毒粒子增殖。第一代整合酶抑制剂雷替拉韦于 2007 年核准，提供了一种抑制爱滋病毒复製的新作用机制。它在临床试验中表现出高效性和良好的耐受性。此后，新一代整合酶抑制剂，如埃替拉韦和多替拉韦，相继开发和核准。与现有的抗爱滋病毒疗法相比，这些药物具有更好的疗效和耐受性。整合酶抑制剂的引入显着扩展了爱滋病毒管理的治疗选择。整合酶抑制剂主要透过抑制病毒整合酶的活性来阻止病毒DNA整合到宿主细胞DNA中，用于治疗爱滋病毒/爱滋病。
市场动态：
全球整合酶抑制剂市场的成长主要得益于全球爱滋病毒/爱滋病负担的不断加重、抗逆转滤病毒治疗(ART) 在爱滋病毒治疗中的应用日益广泛、以及随着新型和改良整合酶抑制剂的推出，产品平臺不断壮大。爱滋病毒/爱滋病盛行率的上升、药物研发的进步以及整合酶抑制剂的有效性和安全性是预测期内推动全球整合酶抑制剂市场成长的关键因素。已开发国家政府在应用抗逆转录病毒疗法方面的优惠倡议提供了有利可图的机会。然而，爱滋病毒抗药性株的出现和整合酶抑制剂治疗的高成本可能会对市场成长产生负面影响。市场的主要企业正致力于长效注射/口服製剂的研究和开发，以提高治疗依从性并推动商机。
本报告的主要特点
- 本报告对全球整合酶抑制剂市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和复合年增长率。
- 它还强调了每个细分市场的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
- 全球整合酶抑制剂市场的主要企业是根据以下参数进行的分析，例如公司概况、产品系列、主要亮点、财务表现和策略。
- 透过本报告的见解，负责人和企业经营团队可以就未来的产品发布、合作伙伴关係、市场扩张和行销策略做出明智的决策。
- 「全球整合酶抑制剂市场」报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
- 相关人员可以透过用于分析全球整合酶抑制剂市场的各种策略矩阵来更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 爱滋病毒/爱滋病的流行、药物开发以及疗效和安全性的进步
- 医疗费用高昂，且担心副作用和安全性
- 具有改善治疗特性的整合酶抑制剂
- 影响分析
- 主要亮点
- 监管情景
- 产品发布/核准
- PEST分析
- 波特五力分析
- 企业合併（M&A）场景
4. 全球整合酶抑制剂市场：COVID-19感染疾病的影响
- COVID-19流行病学
- 供需侧分析
- 经济影响
5. 全球整合酶抑制剂市场（依药物类型划分）（2020-2032 年）
- 雷替拉韦
- 多替拉韦
- 埃替拉韦
- 比克替拉韦
- 其他（卡博特韦等）
6. 依给药途径分類的全球整合酶抑制剂市场（2020-2032）
- 口服
- 静脉
- 其他的
7. 全球整合酶抑制剂市场依通路划分（2020-2032）
- 医院药房
- 零售药局
- 网路药局
8. 全球整合酶抑制剂市场（按地区）（2020-2032）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 印度
- 中国
- 日本
- 澳洲
- ASEAN
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第九章 竞争态势
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc
- Janssen Pharmaceuticals, Inc
- Theratechnologies Inc
- Shionogi & Co., Ltd
- Viatris Inc.
第 10 章 章节
- 分析方法
- 关于出版商
Integrase Inhibitors Market is estimated to be valued at USD 16.43 Bn in 2025 and is expected to reach USD 24.22 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 16.43 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.70% | 2032 Value Projection: | USD 24.22 Bn |
Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.
Market Dynamics:
The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.
Key features of the study:
- This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.
Detailed Segmentation:
- By Drug:
- Raltegravir
- Dolutegravir
- Elvitegravir
- Bictegravir
- Others (Cabotegravir, etc.)
- By Route of Administration:
- Oral
- Intravenous
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Shionogi & Co., Ltd.
- Viatris Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Integrase Inhibitor, By Drug
- Market Integrase Inhibitor, By Route of Administration
- Market Integrase Inhibitor, By Distribution Channel
- Market Integrase Inhibitor, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
- High Treatment Costs, Side Effects and Safety Concerns
- Integrase Inhibitors with improved therapeutic profiles.
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Integrase Inhibitors Market, By Drug, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Raltegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Dolutegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Elvitegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Bictegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Others (Cabotegravir, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
6. Global Integrase Inhibitors Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
7. Global Integrase Inhibitors Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
8. Global Integrase Inhibitors Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViiV Healthcare group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Theratechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi & Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
